Transcript of 研究倫理審查委員會 103 度 第5 次會議 會議紀錄
20140821
153017:30
()()() ()
/
K-333
peretinoin
(PEGASYS® ) (ribavirin)
07/08
/
() 103/06/16~103/08/10
49 9 ( 2 5 2
) 14 ( 3 11 ) 13 ( 3
11 ) 12 ( 4 8 ) 1 (
1 )
101034
103024
103013
103010
100046
101095
102067
102025
102015
-
101095 35
9 14 13 0 12 1 49
() 103 6 16 ~103 8 10
44 ,
/
36
Tenofovir Disoproxil
FumarateTDF
Peginterferon α-2a
and Safety of Tenofovir
Disoproxil Fumarate (TDF) in
Subjects with HBeAg-Positive or
Efficacy of Tenofovir
versus Tenofovir Disoproxil
the Treatment of HBeAg Positive,
Chronic Hepatitis B.
Joint Asia Diabetes Evaluation
of death among hospice
diabetic nephropathy
of ageing for
A Phase 2,
tests (ALT and AST) in
HCV-positive subjects who have
been nonresponsive to prior
ribavirin
/Chi-Yi
Tenofovir Disoproxil
FumarateTDF
Peginterferon α-2a
and Safety of Tenofovir
Disoproxil Fumarate (TDF) in
Subjects with HBeAg-Positive or
Taiwan
2 diabetes
/Lu
Yin-Che
2014/8/7
- 1
- 2
()
(1)- 3
:- 5
:- 6
8 2 2 1
2 1
CYCH-IRB No.103027
2014/07/09 PI ,07/16
:
:
:
11 0 0 0
/ 0
—
*
:PI
*
Asunaprevir Daclatasvir Peginterferon α-2a (Pegasys)
Ribavirin (Copegus) (P/R) (QUAD)/
*
4 5 () 0
0 / 0
:
25 Tenofovir Alafenamide TAF B
e B
300 Tenofovir Disoproxil Fumarate TDF
/
2014/08/08PI
2. 2014 6 13 JIRB JIRB
3. 2014 1 22
:
3 6 0 0
/ 0
:
semaglutide
/
0 ; 0
; 0 ; 0
:
SAE/UP ()
103 06 16 ~103 08 10 SAE/UP
: